[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.31. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 9, 1957

USE OF RESERPINE (SERPASIL) IN THE MANAGEMENT OF CHRONIC ALCOHOLISM

Author Affiliations

Boston

Associate in Medicine, Peter Bent Brigham Hospital; Clinical Associate in Medicine, Harvard Medical School.

JAMA. 1957;163(6):426-429. doi:10.1001/jama.1957.02970410016006
Abstract

• Reserpine was compared with a placebo in 145 studies involving 180 ambulatory patients who underwent treatment for chronic alcoholism. The final comparison involved 33 patients who received the placebo and 112 patients who received either 0.25 or 0.5 mg. of reserpine by mouth twice a day. Whether a given patient was receiving reserpine or the placebo was known to the druggist and secretary, but not to the patient or his physician. At the conclusion of the period of study, of the 112 patients who received reserpine, 80 (71%) were reported as slightly improved, moderately improved, or well; of the 33 (21%) who received the placebo, only 7 were so reported. Improvement was considered significant in more than half of the patients who received reserpine.

×